Neeltje Steeghs

Amsterdam, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 243 publications

ASO Visual Abstract: Patient and Tumor Factors Influencing Diagnostic Trajectories in Gastrointestinal Stromal Tumor Patients and Their Impact on Health-Related Quality of Life: A Dutch Multicenter Study.

ASO Visual Abstract: Patient and Tumor Factors Influencing Diagnostic Trajectories in Gastrointestinal Stromal Tumor Patients and Their Impact on Health-Related Quality of Life: A Dutch Multicenter Study.

Journal: Annals of surgical oncology
Published: June 02, 2026

The impact of pazopanib and extremity radiotherapy on transaminase elevations in soft tissue sarcoma.

The impact of pazopanib and extremity radiotherapy on transaminase elevations in soft tissue sarcoma.

Journal: Acta oncologica (Stockholm, Sweden)
Published: May 26, 2026

Tumor Whole-Genome Sequencing for Prediction of Venous Thromboembolism in Patients With Metastasized Solid Cancer.

Tumor Whole-Genome Sequencing for Prediction of Venous Thromboembolism in Patients With Metastasized Solid Cancer.

Journal: Circulation. Genomic and precision medicine
Published: April 10, 2026

The use of pharmacodynamic results for recommended phase II decision making in oncology clinical trials.

The use of pharmacodynamic results for recommended phase II decision making in oncology clinical trials.

Journal: Cancer chemotherapy and pharmacology
Published: April 01, 2026

Adjuvant Imatinib or Observation in Patients With Gastrointestinal Stromal Tumors With KIT Exon 9 Mutations.

Adjuvant Imatinib or Observation in Patients With Gastrointestinal Stromal Tumors With KIT Exon 9 Mutations.

Journal: JAMA oncology
Published: February 26, 2026

Prediction of Mutations and Outcome in Gastrointestinal Stromal Tumors with Deep Learning: A Multicenter, Multinational Study.

Prediction of Mutations and Outcome in Gastrointestinal Stromal Tumors with Deep Learning: A Multicenter, Multinational Study.

Journal: medRxiv : the preprint server for health sciences
Published: February 12, 2026

Deep Learning Predicts Mutations and Outcomes in Gastrointestinal Stromal Tumors.

Deep Learning Predicts Mutations and Outcomes in Gastrointestinal Stromal Tumors.

Journal: Cancer research
Published: January 12, 2026

Deep Learning Predicts Mutations and Outcomes in Gastrointestinal Stromal Tumors from Whole-Slide Images.

Deep Learning Predicts Mutations and Outcomes in Gastrointestinal Stromal Tumors from Whole-Slide Images.

Journal: Cancer research
Published: January 12, 2026

Exposure-Response Relationships of Antibody Drug Conjugates in Solid Tumours.

Exposure-Response Relationships of Antibody Drug Conjugates in Solid Tumours.

Journal: Clinical pharmacokinetics
Published: January 12, 2026

Biomarkers of activity from a phase I study of cergutuzumab amunaleukin in patients with advanced solid tumors.

Biomarkers of activity from a phase I study of cergutuzumab amunaleukin in patients with advanced solid tumors.

Journal: Journal for immunotherapy of cancer
Published: December 01, 2025

Patient and Tumor Factors Influencing Diagnostic Trajectories in Gastrointestinal Stromal Tumor Patients and Their Impact on Health-Related Quality of Life: A Dutch Multicenter Study.

Patient and Tumor Factors Influencing Diagnostic Trajectories in Gastrointestinal Stromal Tumor Patients and Their Impact on Health-Related Quality of Life: A Dutch Multicenter Study.

Journal: Annals of surgical oncology
Published: December 01, 2025

The SHERPA trial: A phase I study combining SHP2 inhibitor RMC-4630 and ERK inhibitor LY3214996 in patients with KRAS-mutant pancreatic, non-small cell lung and colorectal cancer.

The SHERPA trial: A phase I study combining SHP2 inhibitor RMC-4630 and ERK inhibitor LY3214996 in patients with KRAS-mutant pancreatic, non-small cell lung and colorectal cancer.

Journal: European journal of cancer (Oxford, England : 1990)
Published: November 20, 2025
Showing 1-12 of 243

Last Updated: 09/26/2026